Endometrial Hyperplasia Management
On this page
Direct answer
Endometrial hyperplasia means the endometrial glands have proliferated beyond normal under sustained unopposed oestrogen, and everything about its management flows from one question — is there cytological atypia? The WHO 2014 framework collapses the older four-tier scheme into non-atypical hyperplasia and atypical hyperplasia (endometrioid intraepithelial neoplasia). The prognostic split is stark: non-atypical hyperplasia progresses to carcinoma in only about 1-3 per cent, while untreated atypical hyperplasia harbours coexisting carcinoma in up to a third of hysterectomy specimens and progresses in a substantial minority — hence two diverging pathways. Hysterectomy is definitive for atypical hyperplasia in women who have completed childbearing; the levonorgestrel intrauterine system or oral progestogens for at least six months, with surveillance biopsy, is standard for non-atypical disease and for the young woman with atypia who desires fertility, alongside weight reduction and treatment of the oestrogen excess.
What you must remember
- Classification to quote: WHO 2014 — non-atypical versus atypical hyperplasia/endometrioid intraepithelial neoplasia; the older simple/complex terminology is historical but still appears in Indian vivas.
- Progression numbers: non-atypical about 1-3 per cent over years; atypical hyperplasia progresses in a substantial proportion (older cohort figures near 30 per cent or more) and coexists with grade 1 carcinoma in up to a third of uteri — the argument for surgery.
- Risk-factor engine: unopposed oestrogen from obesity (peripheral aromatisation), PCOS and chronic anovulation, nulliparity, early menarche and late menopause, oestrogen-only therapy, tamoxifen, oestrogen-secreting tumours, Lynch syndrome.
- Diagnosis: endometrial sampling is mandatory — outpatient pipelle or dilatation and curettage with hysteroscopy when focal disease or architectural detail matters; transvaginal ultrasound supports but never replaces histology.
- Non-atypical management: LNG-IUS first line (regression above 80-90 per cent commonly quoted), or cyclic/continuous oral progestogens for three to six months, plus removing the drive — weight loss, treating anovulation, stopping unopposed oestrogen.
- Atypical management: hysterectomy with bilateral salpingo-oophorectomy when family is complete; fertility-sparing progestin therapy (LNG-IUS or high-dose oral) only in strictly counselled young women, with repeat sampling every six months until two consecutive negatives, and hysterectomy after childbearing.
- Tamoxifen caution: any abnormal bleeding on tamoxifen gets sampling; the hyperplasia it causes is often polypoid and atypical.
- Lynch thread: endometrial cancer is often the sentinel malignancy of Lynch syndrome — family history of colorectal and endometrial cancers in a young patient deserves genetics referral.
A worked case with a fork
A 42-year-old with BMI 34, long-standing oligomenorrhoea and PCOS presents with six months of heavy irregular bleeding; pipelle sampling reports atypical hyperplasia. The consultation forks on fertility. With two children, she is counselled that a third or more of such uteri already harbour carcinoma and that total laparoscopic hysterectomy with bilateral salpingo-oophorectomy is guideline-concordant definitive treatment. If she deeply wants another child: hysteroscopy to exclude a focal carcinoma first, then LNG-IUS or high-dose oral progestin for six months, a weight-reduction programme, and repeat biopsy six-monthly until two consecutive negatives; conception is encouraged once regression is confirmed, and hysterectomy follows completed family. If she relapses twice, surgery stops being optional. Contrast her 53-year-old postmenopausal counterpart on tamoxifen with the same histology: her pathway is hysterectomy, because age plus tamoxifen plus atypia stacks the risk of concurrent carcinoma too high to watch.
Where students slip
Three slips recur. First, treating all hyperplasia identically — prescribing progestins for atypical disease in a completed-family patient and forgetting surgery is the guideline answer. Second, quoting the old four-category classification as current and missing the atypia axis when asked how hyperplasia is classified today. Third, forgetting surveillance: progestin therapy without scheduled repeat sampling delays carcinoma diagnoses; the expected cadence is six-monthly biopsy until two consecutive negatives. A quieter slip: relying on ultrasound thickness for follow-up — regression is defined histologically, not sonographically.
Frequently asked questions
How does atypia change the management of endometrial hyperplasia?
Non-atypical disease is treated with progestogens (best via the levonorgestrel intrauterine system) and risk-factor correction, while atypical hyperplasia warrants hysterectomy when fertility is complete, with progestins reserved for selected fertility-seekers.
What is the risk of progression with atypical hyperplasia?
Untreated atypical hyperplasia progresses in a substantial minority — commonly quoted around 30 per cent in older cohorts — and coexisting carcinoma is found in up to about a third of hysterectomy specimens.
Which device gives the highest regression rates?
The levonorgestrel-releasing intrauterine system, delivering high local progestin with minimal systemic exposure, outperforming oral progestogens in comparative studies.
How is a young woman with atypical hyperplasia who wants fertility managed?
Hysteroscopy to exclude carcinoma, then LNG-IUS or high-dose progestins with six-monthly sampling until two consecutive negative biopsies, weight loss, prompt conception, and hysterectomy once family is complete.
Why does tamoxifen cause endometrial pathology?
Tamoxifen acts as a partial oestrogen agonist on the endometrium, producing polyps, hyperplasia and occasionally carcinoma, so abnormal bleeding on tamoxifen requires endometrial sampling.